Clinical Trials
2 trialsNCT05201066 2026-01-07
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Phase 2 Active not recruiting
NCT04093570 2025-10-31
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Taiho Oncology, Inc.
Phase 2 Enrolling by invitation